Merger filing sets dilution terms for Werewolf Therapeutics stock

Published on 10/02/2026 at 04:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The deal values Werewolf at USD 47.50 million and Ambros at USD 500.00 million. Werewolf Therapeutics stock sits at USD 42.8 million market value.

HOWL, US95075A1079, Illustration mit AI erstellt.

Werewolf Therapeutics (US95075A1079) filed a preliminary merger registration statement on September 22, 2026, setting out a proposed combination with Ambros Therapeutics and dilution terms for Werewolf Therapeutics stock. The filing describes a concurrent USD 150.0 million private placement and says the transaction requires stockholder and Nasdaq approvals.

Merger terms reshape ownership

According to the Werewolf Therapeutics filing dated September 22, 2026, the exchange-ratio framework assigns Ambros an equity value of USD 500.0 million and Werewolf an equity value of USD 47.5 million, subject to an adjustment for closing cash.

The proposed transaction would rename Werewolf as Ambros Therapeutics, while the combined company is expected to seek Nasdaq listing under the symbol AMBX. Existing Werewolf holders are expected to receive contingent value rights tied to potential proceeds from legacy INDUKINE assets, but the filing also describes share issuance to Ambros holders and PIPE investors.

Results add a quantified counterpoint

Werewolf reported diluted earnings per share of USD 0.08 for the second quarter of 2026, compared with a consensus loss of USD 0.28, according to Zacks. The comparison is significant because the merger story changes the company profile from an immuno-oncology developer toward Ambros' late-stage rare-disease program.

The transaction also carries execution risk. The S-4 says Werewolf stockholders must approve multiple proposals, including the stock issuance, change of control, reverse split and name change, while Nasdaq must approve the combined company's listing.

Market value and yearly range

HOWL had a market capitalization of USD 42.8 million and a 52-week range of USD 0.27 to USD 2.15 as of October 1, 2026. The valuation gap between Werewolf and Ambros in the filing, together with the proposed ownership changes, makes the approval process central to the stock's investment case.